Edition:
United States

CTI Biopharma Corp (CTIC.O)

CTIC.O on Consolidated Issue listed on NASDAQ Capital Market

1.81USD
20 Aug 2018
Change (% chg)

$-0.02 (-1.09%)
Prev Close
$1.83
Open
$1.84
Day's High
$1.87
Day's Low
$1.75
Volume
325,068
Avg. Vol
558,191
52-wk High
$5.36
52-wk Low
$1.75

Chart for

About

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for... (more)

Overall

Beta: -0.34
Market Cap(Mil.): $106.12
Shares Outstanding(Mil.): 57.99
Dividend: --
Yield (%): --

Financials

  CTIC.O Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -0.89 -- --
ROI: -58.80 2.89 12.63
ROE: -73.82 1.65 14.82

BRIEF-Cti Biopharma Reports Q1 EPS Loss Per Share Of $0.08

* AS OF MARCH 31, 2018, CASH AND CASH EQUIVALENTS TOTALED $104.6 MILLION, COMPARED TO $43.2 MILLION AS OF DECEMBER 31, 2017 Source text for Eikon: Further company coverage:

May 03 2018

BRIEF-Children's Hospital Of Philadelphia Foundation To Engage In Dialogue With Spark Therapeutics To Be Allowed To Designate At Least 1 Board Member

* CHILDREN'S HOSPITAL OF PHILADELPHIA FOUNDATION - TO ENGAGE IN DIALOGUE WITH SPARK THERAPEUTICS TO BE ALLOWED TO DESIGNATE AT LEAST 1 BOARD MEMBER

Mar 09 2018

BRIEF-CTI Biopharma Q4 Loss Per Share $0.33

* CTI BIOPHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 07 2018

BRIEF-Tempest Therapeutics Inc Says It Has Raised $25.2 Million In Equity Financing

* TEMPEST THERAPEUTICS, INC FILES TO SAY IT HAS RAISED $25.2 MILLION IN EQUITY FINANCING - SEC FILING​

Mar 01 2018

BRIEF-Growth Equity Opportunities Fund Reports 6.0 Pct Stake In CTI Biopharma

* GROWTH EQUITY OPPORTUNITIES FUND V LLC REPORTS 6.0 PERCENT STAKE IN CTI BIOPHARMA CORP AS OF FEB 8 - SEC FILING

Feb 20 2018

Earnings vs. Estimates